A Controlled, Randomized, Parallel , Multi-centre Feasibility Study of the Oral Direct Thrombin Inhibitor, AZD0837, Given as ER Formulation, in the Prevention of Stroke and Systolic Embolic Events in Patients With Atrial Fibrillation, Who Are Appropriate for But Unable/Unwilling to Take VKA Therapy
ООО «АстраЗенека Фармасьютикалз»
Контакты компании
- Сайтastrazeneca.ru
- Телефон+7 (495) 799-56-99
Указал администратор Клиномира · обновлено 10.11.2026. Это контакты самой организации: Клиномир не передаёт ей ваши данные.
Специалисты компании
Личные визитки людей, которые сами указали это место работы и разрешили показ здесь. Имена из реестров мы не берём.Пока никто не показал здесь свою визитку.
Нашли ошибку или чужую визитку? Сообщить модератору
Разрешения по годам
Фазы
Области
Центры, где идут исследования
Исследования
Открыть в каталоге с фильтрамиAn Open-label, Non-comparative, Multi-centre Study to Assess the Efficacy and Safety of Bicalutamide When Used in Combination With Anastrozole for the Treatment of Gonadotropin-independent Precocious Puberty in Boys With Testotoxicosis
A 24-week International, Randomized, Parallel-group, Double-blind, Placebo-controlled Phase III Study With a 80-week Extension Period to Evaluate the Efficacy and Safety of Dapagliflozin Therapy When Added to the Therapy of Patients With Type 2 Diabetes With Inadequate Glycaemic Control on Insulin
A Multicentre, Randomised, Double-Blind, Placebo-Controlled Phase IV Trial to Evaluate the Effect of Saxagliptin on the Incidence of Cardiovascular Death, Myocardial Infarction or Ischaemic Stroke in Patients With Type 2 Diabetes
National Multicentre Non-interventional Study to Assess CRT Patterns and Short-term Outcomes on Unresectable NSCLC and SCLC in Routine Practices in Russia
Multi-centre, Double-blind, Randomised, Parallel-group, Placebo-controlled, Phase 3 Study of the Efficacy & Safety of Quetiapine Fumarate & Lithium as Monotherapy in Adult Patients With Bipolar Depression for 8 Weeks & Quetiapine in Continuation (Abbreviated)
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial to Evaluate the Efficacy and Safety of Saxagliptin as Monotherapy With Titration in Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control With Diet and Exercise
Observational Non-interventional Study on the Use of International GerdQ Questionnaire for the Diagnosis of Gastroesophageal Reflux Disease in the Russian Practice
Multicentre, Single Arm, Non-interventional, Observational, Prospective Study to Assess Demographic Characteristics, Burden of Disease and Short-term Patient Reported Outcomes on Symptom Relief in Severe Asthma Patients Aged Older Than 12 Qualifying for Treatment With Tezepelumab in Russia
An epidemiOlogy Study to deteRmine the Prevalence of EGFR muTations in RUSsian Patients With Advanced NSCLC (ORTUS)
A Randomised, Double Blind, Placebo Controlled, Phase IIb Dose Ranging Study (With Open-label Etanercept Treatment Group) to Investigate Efficacy, Safety and Pharmacokinetics of AZD5672 Administered for 12 Weeks to Rheumatoid Arthritis Patients Receiving Methotrexate.
A Multicountry, Multicentre, Noninterventional, Retrospective Study to Describe the Real-world Management Outcomes in Patients With Unresectable Hepatocellular Carcinoma
A Multi-centre, Double-blind, Double-dummy, Placebo Controlled Parallel Group Randomized Phase IIb Proof of Concept Study With 3 Oral Dose Groups of AZD3480 or Donepezil During 12 Weeks Treatment in Patients With Alzheimer's Disease
A Multicenter, Single Arm, Non-interventional, Observational, Prospective Study to Assess Demographic Characteristics, Burden of Disease and Short-term Patient Reported Outcomes on Symptom Relief in Severe Eosinophilic Asthma Patients Aged Older Than 18 Qualifying for Treatment With Benralizumab in Russia
Observational Multicenter Non-interventional Study on COPD Patients Treatment Strategies at the Time of Hospital Discharge and Within 12 Months of Follow-up on an Outpatient Primary Care Basement
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase 3 Trial to Evaluate the Safety and Efficacy of Dapagliflozin as Monotherapy in Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control With Diet and Exercise
Observational Retrospective Multicenter Study to Evaluate Clinical Outcome Variables Change With dapaGLiflozin Treatment Introduced in Patients With T2D uncOntrolled by the Current Therapy in Real Clinical Practice in RussIA
ALICIA (Observational Prospective Study of Acalabrutinib in CLL Therapy in Real Clinical Practice in Russia)
A Comparative Study of Inhaled Ciclesonide Versus Placebo in Children With Asthma
BREAKOUT -International Breast Cancer Biomarker, Standard of Care and Real World Outcomes Study
Как компания названа в реестрах (23)
- "АстраЗенека АБ"
- AstraZeneca
- AstraZeneca AB
- AstraZeneca AB, АстраЗенека АВ
- «АстраЗенека АБ»
- «АстраЗенека АВ»
- Астра Зенека АБ
- Астра Зенека АБ (AstraZeneca AB)
- АстраЗенека
- АстраЗенека AB
- АстраЗенека AБ
- АстраЗенека АБ
- АстраЗенека АБ (AstraZeneca AB)
- АстраЗенека АВ
- АстраЗенекаАБ
- АстреЗенека АБ
- ООО "АстраЗенека Фармасьютикалз"
- ООО "АстраЗенека Фармасьютикалз", Россия
- ООО «АстраЗенека Фармасьютикалз» (адрес представительства: 119334
- Общество с Ограниченной Ответственностью "АстраЗенека Фармасьютикалз"
- Общество с Ограниченной Ответственностью "АстраЗенека Фармасьютикалз", Россия
- Общество с ограниченной ответственностью "АстраЗенека Фармасьютикалз"
- Общество с ограниченной ответственностью «АстраЗенека Фармасьютикалз»